Engineering Targeted mRNA LNPs to Enable In Vivo Immunotherapy for Autoimmune Diseases

• NHP data demonstrating the potential of targeted mRNA LNPs to enable in vivo immunotherapy for autoimmune disease models
• Robust B-cell depletion across peripheral blood, spleen, and lymphoid tissues using a proprietary targeted LNP delivery platform
• Evidence of immune reset biology with emerging safety and tolerability supporting continued preclinical development

Speakers:

Zach Zhu

Chief Technology Officer

Innorna